The main purpose of this study is to determine the electrophysiological effects of
cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer
disease. The attempt will be to locate electrophysiological markers and predictors of
cognitive and clinical treatment response.
Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state
exam scores between 15-27), and normal controls (age generally between 60-85). Subjects
must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or
willing to try a transdermal nicotine patch for two 8 hour periods.